EGFR and head and neck squamous cell carcinoma: Cetuximab resistance in HNSCC was investigated using 89Zr-cetuximab, and the study found that it was a suitable radiopharmaceutical to identify EGFR downregulation in vitro and in vivo, demonstrating the potential applicability for monitoring patient resistance during cetuximab therapy (140).